Human Epithelial neutrophil activating peptide 78 (ENA-78/CXCL5) ELISA Kit

Code CSB-E08178h
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
chemokine (C-X-C motif) ligand 5
Alternative Names
AMCFII ELISA Kit; C-X-C motif chemokine 5 ELISA Kit; C-X-C motif chemokine ligand 5 ELISA Kit; Chemokine (C X C motif) ligand 5 ELISA Kit; chemokine (C-X-C motif) ligand 5 ELISA Kit; Cxcl5 ELISA Kit; CXCL5_HUMAN ELISA Kit; ENA 78 ELISA Kit; ENA-78 (8-78) ELISA Kit; ENA-78(1-78) ELISA Kit; ENA-78(9-78) ELISA Kit; ENA78 ELISA Kit; Epithelial derived neutrophil activating protein 78 ELISA Kit; Epithelial-derived neutrophil-activating protein 78 ELISA Kit; Lipopolysaccharide-induced CXC chemokine ELISA Kit; Neutrophil activating peptide ENA 78 ELISA Kit; Neutrophil activating protein 78 ELISA Kit; Neutrophil-activating peptide ENA-78 ELISA Kit; neutrophil-activating protein 78 ELISA Kit; SCYB5 ELISA Kit; Small inducible cytokine B5 ELISA Kit; small inducible cytokine subfamily B (Cys-X-Cys); member 5 (epithelial-derived neutrophil-activating peptide 78) ELISA Kit; small inducible cytokine subfamily B; member 5 ELISA Kit; Small-inducible cytokine B5 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.625 ng/mL-40 ng/mL
0.567 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
To assess the linearity of the assay, samples were spiked with high concentrations of human ENA-78/CXCL5 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 98    
Range % 94-103    
1:2 Average % 102    
Range % 97-105    
1:4 Average % 86    
Range % 83-89    
1:8 Average % 97    
Range % 94-100    
The recovery of human ENA-78/CXCL5 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
Sample Type Average % Recovery Range    
Serum (n=5) 85 81-89    
EDTA plasma (n=4) 98 94-103    
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
ng/ml OD1 OD2 Average Corrected    
40 2.282 2.204 2.243 2.131    
20 1.362 1.368 1.365 1.253    
10 0.781 0.757 0.769 0.657    
5 0.435 0.445 0.440 0.328    
2.5 0.304 0.316 0.310 0.198    
1.25 0.214 0.205 0.210 0.098    
0.625 0.188 0.184 0.186 0.074    
0 0.114 0.110 0.112      
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

The product CSB-E08178h is a sandwich ELISA kit developed to measure levels of human ENA-78 in multiple samples, including serum, plasma, or tissue homogenates. This assay uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of ENA-78 in samples. The color intensity is measured at 450 nm via a microplate reader.

ENA-78, alternatively referred to as CXCL5, is identified as an inflammatory mediator with a powerful role in neutrophil chemotaxis. CXCL5 is upregulated in many cancers including gastric cancer, hepatocellular carcinoma (HCC), breast cancer, and bladder cancer, and is involved in tumor growth and metastasis. In the tumor microenvironment (TME), CXCL5 binds to CXCR2 and participates in the recruitment of immune cells, and promotes angiogenesis, tumor growth, and metastasis. The CXCL5/CXCR2 axis can act as a bridge between tumor cells and host cells in TME. Blocking the transmission of CXCL5/CXCR2 signals can increase the sensitivity and effectiveness of immunotherapy and slow down tumor progression.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.
Gene References into Functions
  1. Serum CXCL5 levels from pemphigus vulgaris patients are significantly higher than those in bullous pemphigoid patients and healthy controls. PMID: 27501402
  2. These data demonstrated that CXCL5 expression was upregulated in prostate cancer tissues and that exogenous CXCL5 protein exposure or CXCL5 overexpression promoted malignant phenotypes of prostate cancer cells in vitro and in vivo. PMID: 29749439
  3. activated CXCL5-CXCR2 axis contributes to the metastatic phenotype of PTC cells by modulating Akt/GSK-3beta/beta-catenin pathway PMID: 29471001
  4. study elucidates the important role of CXCL5 in the progression and prognosis of NSCLC. These findings suggested that CXCL5 might be a potential biomarker and novel therapeutic target for lung cancer PMID: 29526026
  5. PERK-p-eIF2alpha pathway could suppress metastasis in triple-negative breast cancer by inhibiting expression of PDL1 and CXCL5 in tumor cells. PMID: 29053414
  6. Mechanistically, AR modulated cytokine CXCL5 expression by altering AKT --> NF-kappaB signaling, and interruption of AKT --> NF-kappaB --> CXCL5 signaling using either specific inhibitors or siRNA suppressed AR-enhanced EC recruitment and AR-EC-promoted RCC progression. PMID: 27848972
  7. Curcumin suppressed CXCL5 expression by direct inhibition of IKKbeta phosphorylation, and inhibition of p38 MAPK via induction of negative regulator MKP-1. PMID: 27538525
  8. The CXCL5 and the overexpression of miR-141 reduced levels of MMP-2 and MMP-9 in tumor necrosis factor-alpha-treated HT29 cells by means of repressing the inhibitory AKT. PMID: 28854064
  9. CXCL5 may promote mitomycin resistance by activating EMT and NF-kappaB pathway. Thus, this study identifies CXCL5 as a novel chemoresistance-related marker in non-muscle invasive bladder cancer PMID: 29545183
  10. findings for the first time provided evidence that ENA78 may play a key role of mediator in pathogenesis of Major Depressive Disorder(MDD) and in the mechanism of vinlafaxine effects on MDD. PMID: 28441588
  11. our findings support CXCL5 as a promoter of colorectal cancer metastasis and a predictor of poor clinical outcomes in colorectal cancer patients. PMID: 28356111
  12. CXCL5 levels were decreased in LSCC patient serum. PMID: 27876461
  13. a finely tuned balance between the GAG-bound dimer and free soluble monomer regulates CXCL5-mediated receptor signaling and function. PMID: 27471273
  14. CXCL5 plays a promoting role in glioma in autocrine- and paracrine-dependent manners. PMID: 27748886
  15. The expression of CXCL5 is up-regulated in osteosarcoma cells. PMID: 28277189
  16. CXCL5 expression in urine is related to bladder cancer TNM stage, lymph node metastasis, tumor size, and tumor grade. PMID: 26503215
  17. ENA 78 plasma levels were correlated with Expanded Disability Status Scale scores in neuromyelitis optica (NMO) patients; elevated secretion of ENA 78 may be a critical step in neutrophil recruitment during the remission of NMO. PMID: 27401736
  18. CXCL5 expression is enriched in human atherosclerotic coronary artery. The CXCL5 variant might be a genetic risk factor for the susceptibility of CAD and the CXCL5 promoter -156 G/C C allele might be an independent predictor for CAD. PMID: 26287498
  19. Study shows that CXCL5 expression is elevated in positive correlation to bladder cancer grade and promotes cell migration and invasion via binding to its receptor CXCR2. PMID: 26058729
  20. Analysis of monocultured dermal fibroblasts and keratinocytes revealed that only fibroblasts but not keratinocytes displayed up regulated CXCL5 levels after UV stimulation. PMID: 25690483
  21. There was an inverse correlation between DACH1 mRNA levels and CXCL5 in both lung cancer cell lines and human NSCLC tissues. PMID: 25788272
  22. High CXCL5 expression is associated with pediatric ulcerative colitis. PMID: 25738378
  23. the increased level of CXCL5 in tissue compartments, including the central nervous system of HIV-1-infected individuals might alter the inflammatory response through the infiltration of neutrophils into tissue compartment PMID: 25536401
  24. Serum levels of ENA-78 were elevated in autistic children and they were significantly associated with the increased levels of serum antineuronal auto-antibodies PMID: 25871636
  25. This study aims to evaluate serum levels of ENA78/CXCL5 and SDF-1/CXCL12 along the gastric cancer carcinogenesis, and analyze their clinical significance, and diagnostic potentials through human serum samples. PMID: 25689618
  26. our data showed that the CXCR2/CXCL5 axis contributes to EMT of HCC cells through activating PI3K/Akt/GSK-3beta/Snail signaling, and it may serve as a potential therapeutic target. PMID: 25462858
  27. Solution structure of CXCL5--a novel chemokine and adipokine implicated in inflammation and obesity PMID: 24695525
  28. the expression levels of CXCL5 proteins were decreased in dermal blood vessels of early stage diffuse cutaneous systemic sclerosis PMID: 24292093
  29. data indicates that LCCs per se may act as the producer and receptor of CXCL5 responsible for liver cancer migration and invasion PMID: 25011526
  30. Citrullinated ENA-78/CXCL5 is highly correlated with rheumatoid arthritis disease activity and, unlike noncitrullinated ENA-78/CXCL5, recruits monocytes. PMID: 24943990
  31. CXCL5 showed a statistically significant prognostic effect PMID: 24500664
  32. mRNA and protein of CXCL5 is increased in bladder tumor tissues and cell lines; down-regulation of CXCL5 resulted in significantly decreased cell proliferation, migration and increased cell apoptosis through Snail, PI3K-AKT and ERK1/2 signaling pathways. PMID: 24583128
  33. Knockdown of HSP27 by shRNA decreased HB-EGF plus CXCL5-mediated tumor spheroid formation in a three-dimensional culture system, suggesting that AKT/HSP27 was required for HB-EGF/CXCL5-mediated cancer progression PMID: 24346967
  34. Liver cancer cells with high metastatic potential have a higher expression of CXCL5. Exogenous CXCL5 can increase the proliferation, migration and invasion of liver cancer cells with low metastatic potential. PMID: 23290114
  35. sCXCL5 level was determined to be an independent prognostic factor for NPC patients PMID: 23469080
  36. Increased levels of CXCL5 contribute to enhanced levels of RANKL expression in Paget's disease of bone. PMID: 23439434
  37. CXCL5 gene polymorphisms are functional and associated with variable blood pressure in cardiovascular disease-free individuals. PMID: 23245743
  38. CXCL5 promotes HCC cell proliferation, invasion, and intratumoral neutrophil infiltration. PMID: 22711685
  39. Preoperative serum CXCL5 could serve as a novel predictive marker for prognosis determination of colorectal cancer patients. PMID: 22197219
  40. Endothelial production of both ENA-78 and IL-8 was induced by the proinflammatory cytokine IL-1beta. PMID: 22274300
  41. Serum CXC ligand 5 is a new marker of subclinical atherosclerosis in type 2 diabetes. PMID: 21609350
  42. Blockade of CXCL5 can modulate IL-17-induced arthritic inflammation in part by reducing joint blood vessel formation through a non-overlapping IL-17 mechanism. PMID: 21779896
  43. Data demonstrate that the chemokine CXCL5 is a peripheral mediator of UVB-induced inflammatory pain, likely in humans as well as rats. PMID: 21734176
  44. Plasma CXCL5 levels are lower in patients with chronic liver disease, suggesting that CXCL5 might be involved in the pathogenesis of chronic liver disease. PMID: 21332547
  45. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway. PMID: 20945384
  46. Report influence of troglitazone, sodium butyrate, 5-aminosalicylic acid and BAY 11-7082 on the chemokine ENA-78/CXCL5 secretion in the intestinal subepithelial myofibroblasts. PMID: 21229889
  47. CD14 and CXCL5 were both expressed in tunica intima and tunica adventitia of adipose tissue blood vessels; CXCL5 exhibited chemoattractant and angiogenic properties. PMID: 21034724
  48. The highly divergent effects of modifications of CXCL5 on neutrophil influx underline the potential importance of tissue-specific interactions between chemokines and PAD or proteases. PMID: 20630876
  49. expression in gingival epithelial cells is induced by thrombin via activation of protease-activated receptor 1 PMID: 19567485
  50. Elevated circulating CXCL5 concentrations were associated with higher risk of hypercholesterolemia in middle-aged and elderly Chinese independent of obesity, inflammation, adipokines, and other risk factors but not insulin resistance. PMID: 20501684

Show More

Hide All

Subcellular Location
Protein Families
Intercrine alpha (chemokine CxC) family
Database Links

HGNC: 10642

OMIM: 600324

KEGG: hsa:6374

STRING: 9606.ENSP00000296027

UniGene: Hs.89714

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1